A new rational approach to reach LDL-cholesterol concentration objectives after an acute coronary syndrome

[1]  G. Hindricks,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. , 2017, Revista espanola de cardiologia.

[2]  Jennifer G. Robinson,et al.  Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry , 2017, American heart journal.

[3]  S. Basili,et al.  Treatment and Response to Statins: Gender-related Differences. , 2017, Current medicinal chemistry.

[4]  V. Raparelli,et al.  Gender related differences in treatment and response to statins in primary and secondary cardiovascular prevention: The never‐ending debate , 2017, Pharmacological research.

[5]  N. Salvatella,et al.  Secondary prevention strategies after an acute ST-segment elevation myocardial infarction in the AMI code era: beyond myocardial mechanical reperfusion , 2017, BMC Cardiovascular Disorders.

[6]  A. Hoes,et al.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. , 2016, European heart journal.

[7]  Á. Cequier,et al.  Degree of Lipid Control in Patients With Coronary Heart Disease and Measures Adopted by Physicians. REPAR Study. , 2016, Revista espanola de cardiologia.

[8]  Á. Cequier,et al.  Grado de control lipídico en pacientes coronarios y medidas adoptadas por los médicos. Estudio REPAR , 2016 .

[9]  Brian A Ference,et al.  Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. , 2016, JAMA.

[10]  G. Nilsson,et al.  Low use of statins for secondary prevention in primary care: a survey in a northern Swedish population , 2016, BMC Family Practice.

[11]  Stefan Störk,et al.  EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries , 2016, European journal of preventive cardiology.

[12]  S. Nicholls,et al.  Men and women--similar but not identical: insights into LDL-lowering therapy in women from the Cholesterol Treatment Trialists Collaboration. , 2015, Future cardiology.

[13]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[14]  L. Masana,et al.  IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"? , 2015, Atherosclerosis.

[15]  N. Plana,et al.  [Update of planning tables of cholesterol-lowering therapy orientated to achieve LDL therapeutic targets]. , 2015, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

[16]  Barry J. Davis,et al.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials , 2015, The Lancet.

[17]  C. Ballantyne,et al.  Is High‐Intensity Statin Therapy Associated With Lower Statin Adherence Compared With Low‐ to Moderate‐Intensity Statin Therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines , 2014, Clinical cardiology.

[18]  P. Ridker,et al.  Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. , 2014, Journal of the American College of Cardiology.

[19]  R. Elosua,et al.  Pilot study to validate a computer-based clinical decision support system for dyslipidemia treatment (HTE-DLP). , 2013, Atherosclerosis.

[20]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[21]  N. Murga,et al.  Inercia terapéutica en el manejo extrahospitalario de la dislipemia en pacientes con cardiopatía isquémica. Estudio Inercia , 2010 .

[22]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[23]  N. Plana,et al.  [Tables for cholesterol lowering therapy planning. An update]. , 2010, Medicina clinica.

[24]  N. Plana,et al.  PlanificaciÓn del tratamiento de la hipercolesterolemia orientada a la obtenciÓn de objetivos , 2005 .

[25]  M. Pfeffer,et al.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[26]  M. Pignone,et al.  Drug treatment of hyperlipidemia in women. , 2004, JAMA.

[27]  R. Moore,et al.  Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomised, double blind trials , 2003, BMC family practice.

[28]  Michael F. Oliver,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.

[29]  D. Hunninghake,et al.  Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) , 1998, The American journal of cardiology.

[30]  J. Gómez-Barrado,et al.  Control lipídico en pacientes con enfermedad coronaria del Área de Salud de Cáceres (España): estudio LIPICERES , 2017 .

[31]  R. Califf,et al.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[32]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. , 2012, Lancet.